Canbridge Pharmaceuticals Incis A Global Biopharmaceutical Company Based In Chinaestablished In 2017 And Listed On The Hong Kong Stock Exchangethe Company Is Committed To Researchingdevelopingand Commercializing Therapies For Rare Diseasesit Focuses On Conditions Such As Lysosomal Storage Disordershemophilia Aand Neuromuscular Diseasescollaborating With Leading Researchers And Biotech Firms To Enhance Its Therapeutic Pipeline The Company Has A Diverse Drug Portfolio That Includes Three Approved Drugs And Eight Assets In Developmentnotable Products Are Hunterasean Enzyme Replacement Therapy For Mucopolysaccharidosis Type Iiand Livmarlian Oral Treatment For Rare Cholestatic Liver Diseasescanbridge Operates From Multiple Locationsincluding Beijingshanghaihong Kongtaiwanand Burlingtonmausasupporting Its Global Outreach And Engagement In The Biopharmaceutical Sector
